NBNikki Bozinoff

Nikki Bozinoff

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Nikki Bozinoff has a total of 108 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Opioid agonist therapy in and beyond the COVID-19 pandemic: A descriptive policy analysis across Canadian jurisdictions

    by Andrea Bowra, Tate HubkaRao, Graham MacDonald, Sofie Naeem, Lara Nixon, Ginette Poulin, Kellia Chiu, Nikki Bozinoff, Kelsey MacIntosh, Kelsey Dumont, et al.

  • Open Access

    Characterizing trends and patterns in benzodiazepine-related toxicity deaths in Ontario: A descriptive cross-sectional study

    by Tonya Campbell, Shaleesa Ledlie, Pamela Leece, Joanna Yang, Bisola Hamzat, Gillian Kolla, Nikki Bozinoff, Rob Boyd, Mike Franklyn, Ashley Smoke, et al.

    Objectives: The unregulated drug supply in Canada increasingly contains benzodiazepines, particularly those not approved for medical use, raising concerns about toxicity risk, especially when combined with opioids. Therefore, we aimed to describe trends in benzodiazepine-related toxicity deaths and compare their characteristics and circumstances by benzodiazepine type. Methods: We conducted a descriptive cross-sectional study of accidental benzodiazepine-related toxicity deaths in Ontario between January 1, 2018 and June 30, 2022, using linked administrative healthcare at ICES including coroner’s investigation records from the Drug and Drug/Alcohol Related Death Database. We measured monthly crude rates of benzodiazepine toxicity deaths and summarized characteristics (age, sex, region of residence, etc.) and circumstances (number and types of substances involved, healthcare encounters for toxicities and substance use disorders, etc.) of decedents and compared these by benzodiazepine type (approved vs. not approved for medical use in Canada). Results: Between January 2018 and June 2022, 782 Ontarians died of benzodiazepine-related toxicity (median age of 40 years), of which 70.5% were male and 88.6% resided in Southern Ontario The rate of benzodiazepine toxicity death peaked in December 2020 (0.27 per 100,000; N = 40). Overall, 98.1% of benzodiazepine deaths involved another substance, most commonly opioids (91.2%). Moreover, one-fifth (22.6%) of decedents had experienced a hospital-treated substance toxicity in the year prior to death, and almost two-thirds (64.1%) had a healthcare encounter with a substance use disorder diagnosis in the prior five years. Conclusion: Benzodiazepines remain an important contributor to substance-related mortality in Ontario, with nearly 800 benzodiazepine-related toxicity deaths observed over a four-and-a-half-year period. As almost all deaths involved multiple substances, most commonly opioids, harm reduction and treatment programs must adapt to the evolving needs of people who use drugs who may experience both intentional and unintentional benzodiazepine exposure.

  • Open Access

    Association between initial benzodiazepine prescribing patterns and time to benzodiazepine discontinuation: A population-based retrospective cohort study

    by Nikki Bozinoff, Tanya S. Hauck, Robert A. Kleinman, Matthew E. Sloan, Beth A. Sproule, Simone N. Vigod, Jennifer Wyman, Priscila Pequeno, Tara Gomes

    Background: Long-term benzodiazepine use has been associated with increased risk of morbidity and mortality. Preventing long-term use through safer prescribing practices has received little attention to date. We sought to better understand associations between initial prescription characteristics and duration of benzodiazepine use. Methods and findings: This was a retrospective population-based cohort study of 1,820,808 adults in Ontario with incident benzodiazepine prescriptions between January 1, 2013 and December 31, 2020, with follow-up to December 31, 2021. The primary exposure was duration of the index prescription (≤7 days—referent group, 8–14 days, 15–30 days, or >30 days). Secondary exposures were: (a) duration of action of index benzodiazepine(s) prescription (short-acting, long-acting or both); (b) number of benzodiazepine dispensed on index (1 or 2+); and (c) mean daily dose of the index prescription in Diazepam Milligram Equivalents (DMEs). The primary outcome was time to benzodiazepine discontinuation in days. Multivariable models were adjusted for age, sex, anxiety, insomnia, and substance use disorders as well as other important comorbidities and socio-demographic characteristics. The median age at index was 53 years (Interquartile Range (IQR) 38–67), and 62.6% were women. The median time to discontinuation in women was 16 days (IQR: 6–29) while the median time to discontinuation in men was 19 days (IQR: 6–29). Lorazepam was the most commonly prescribed benzodiazepine on index (63.9%), followed by clonazepam (17.3%) and diazepam (5.8%). In multivariable Cox Proportional Hazards Models, longer index prescriptions were associated with a lower likelihood of benzodiazepine discontinuation (adjusted Hazard Ratio (aHR) 0.54 (95% Confidence Interval (CI) [0.54,0.54]) for 8–14 days; aHR 0.26 (95% CI [0.25,0.26] for 15–30 days and aHR 0.14 (95% CI [0.14,0.14]) for >30 days, compared to ≤7 days, respectively). Being prescribed two or more benzodiazepines versus 1 was also associated with a reduced likelihood of discontinuation (aHR 0.59 (95% CI [0.57,0.61])), as was being prescribed long-acting benzodiazepines (aHR 0.80 (95% CI [0.80,0.80])) or a combination of short and long acting benzodiazepine (aHR 0.84 (95% CI [0.80,0.88])) versus short-acting benzodiazepines alone. Mean daily doses of >5 to ≤10 DME and >10 to ≤20 DME were associated with an increased likelihood of discontinuation (aHR 1.03 (95% CI [1.03,1.03]); aHR: 1.03 (95% CI [1.03,1.04])), whereas doses >20 DME were associated with a reduced likelihood of discontinuation (aHR 0.98 (95% CI [0.97,0.98])) compared with ≤5 DME. Findings may be subject to bias from unmeasured confounding. Conclusion: This large population-based cohort study found that prescribing shorter courses of benzodiazepines, use of a single benzodiazepine, use of a short-acting agent, were associated with reduced likelihood of long-term benzodiazepine use. Findings suggest that simple changes to prescribing practices could reduce prolonged benzodiazepine use and the morbidity and mortality associated with long-term use of these medications.


  • Open Access

    Association between early methadone dose titration and treatment discontinuation and opioid toxicity: A retrospective cohort study

    by Ria Garg, Jin Luo, Nikki Bozinoff, Beth Sproule, Tony Antoniou, Jennifer Wyman, Pamela Leece, Charlotte Munro, Jes Besharh, Tara Gomes

    Background: Clinical guidance in Canada and the United States recommends faster methadone dose titration for individuals using fentanyl. An initial dose increase is recommended between days 4 and 6, but the impact on patient outcomes remains unclear, particularly when provided in an outpatient setting. Therefore, we evaluated the association between early methadone dose titration (i.e., within treatment days 4–6) and treatment discontinuation and opioid toxicity. Methods and findings: We conducted a retrospective propensity-score weighted cohort study of Ontario residents who initiated methadone in an outpatient setting between January 2017 and December 2022. Exposure was defined as provision of a dose titration between treatment days 4–6, with the index date defined as the first date of dose increase. For unexposed individuals, the index date was randomly assigned and followed the same distribution as those exposed. Individuals were followed for up to 181 days following index date for study outcomes. Primary outcomes included methadone discontinuation and opioid toxicity, using an intention-to-treat approach. Secondary outcomes included methadone versus non-methadone-related toxicity while on treatment. We fit a propensity-score model to estimate the probability of dose titration, conditional on baseline demographic and clinical (e.g., comorbidities, past medication use) variables. Propensity score weighted Cox proportional hazard models were then estimated to determine the association between early dose titration and study outcomes. Among 13,560 incident methadone recipients (61.4% [ N = 8,322] provided early dose titration), the mean age was 36.5 years old, and approximately one-third were female. Individuals who received an early dose titration had a lower weighted hazard of discontinuation, which was most pronounced during the first seven days of follow-up (weighted hazard ratio [wHR]: 0.55; 95% confidence interval [CI]: 0.51, 0.60), with attenuation towards the null over time. The observed weighted rate of opioid toxicity was lower among those exposed versus unexposed (10.1 versus 12.3 per 100 person-years; wHR: 0.82; [95% CI: 0.69, 0.97]). Early dose titration was not associated with opioid toxicity while on treatment. Most toxicities were attributed to non-methadone opioids (exposed: 3.89 per 100 person-years versus unexposed: 4.06 per 100 person-years; wHR: 1.00; [95% CI: 0.70, 1.44]). Methadone-related toxicity while on treatment remained low and comparable between exposed and unexposed groups (2.02 versus 2.65 per 100 person-years; wHR: 0.80; [95% CI: 0.46, 1.41]). The main study limitation is the lack of information on drug use history and time-varying clinical factors that may influence both dose titration and subsequent outcomes, introducing the potential for residual confounding. Conclusions: This population-based analysis demonstrated that early methadone dose titration was associated with improved treatment retention and lower hazard of opioid toxicity. Logistical barriers that hinder timely provision of dose increases must be addressed to improve methadone retention among people who use fentanyl.

  • Open Access

    “It beats the hell out of going to a hospital”: service user experiences of telemedicine-based symptom-triggered alcohol withdrawal management

    by Nikki Bozinoff, Divya Prasad, Ke Bin Xiao, Anthony Ngoy, Bernard Le Foll, Anna Gordezky, Christian S. Hendershot, Sandra LaFleur, Lena C. Quilty, Victor M. Tang, et al.

    Introduction: Increasingly, services for the management of substance use disorders have been developed or adapted for remote delivery. Limited research has investigated service user experience of these services. We undertook a qualitative sub-study, embedded within a pilot feasibility study of remote symptom-triggered alcohol withdrawal management, to better understand the experiences of participants. Our aim was to determine the acceptability of the intervention and refine intervention procedures. Methods: Eligible participants were enrolled in the parent study and completed at least one day of telemedicine-delivered symptom-triggered alcohol withdrawal management. Individuals were adults with alcohol use disorder recruited using intensity sampling. Participants completed an audio-recorded, semi-structured interview. Thematic analysis was conducted using Braun and Clarke interpretive methodology. Results: Fourteen individuals were enrolled in the study. Six themes were identified: benefits of being in the home environment, technological tensions, intervention-specific feedback, personal motivations for participation, post-program achievements and changes and navigating the ‘system’. Participants identified numerous benefits of being in the home environment including: increased comfort, privacy and security, normalizing abstinence in the home, flexibility to engage in other tasks, and the convenience of not travelling. Intervention-specific feedback included positive aspects of the intervention (interactions with staff, accountability, counselling, use of medication), areas for improvement (preparation, scheduling, medication logistics, and aftercare), and the meaning and role of having a support person available during treatment. Conclusion: Participants found remote alcohol withdrawal management to be satisfactory and associated with several benefits including increased comfort, privacy, normalizing abstinence in the home, flexibility and convenience. They also provided important feedback for refinement of the intervention. Findings suggest that remote alcohol withdrawal management could play an important role in improving access to medical management of alcohol withdrawal, particularly in rural, remote or underserved areas.

  • Uptake of Low-dose Buprenorphine Initiation and Associated Patient Characteristics in British Columbia, Canada: A Population-based Cohort Study

    by Nikki Md Bozinoff, Jingxin Lei, Tamara Bsc (Pharm) Mihic, Jessica Md Moe, Heather Palis, Seonaid Nolan, Lianping Ti, Mary Clare Kennedy

    Objectives: To characterize patterns of outpatient buprenorphine induction and examine factors associated with the use of low-dose initiation (LDI). Methods: A retrospective cohort study of 4510 adults initiating buprenorphine between January 1, 2016 and December 31, 2019 in British Columbia (BC), Canada, was undertaken using linked administrative data in the Provincial Overdose Cohort, which contains a 20% random sample of BC residents. Using multivariable modelling, we examined the association between sociodemographic, co-morbidity, treatment, and health service utilization variables, and the outcome of LDI. Joinpoint analysis was also conducted to assess inflection points in the prevalence of this practice. Results: Overall, 7.2% of included buprenorphine inductions during the study period were classified as LDI. Joinpoint analysis revealed that the percentage of buprenorphine inductions classified as LDI increased significantly beginning in the fourth quarter of 2017. In multivariable analyses, factors positively associated with LDI included: older age (adjusted odds ratio [aOR]: 1.01, 95% CI: 1.00–1.02), living in Vancouver Coastal (aOR: 1.53, 95% CI: 1.13–2.06) and Fraser Health Authority regions (aOR: 2.56, 95% CI: 1.89–3.48) (vs interior region); having been prescribed slow-release oral morphine for opioid use disorder in the last 3 years (aOR: 4.03, 95% CI: 2.51–6.49), and having 1 (aOR: 2.40, 95% CI: 1.80–3.20) or ≥2 (vs 0) opioid agonist treatment episodes in the last 5 years (aOR: 2.56, 95% CI: 1.89–3.48). Factors negatively associated with microinduction included: male sex (aOR: 0.50, 95% CI:0.41–0.61), alcohol use disorder (aOR: 0.62, 95% CI: 0.40–0.96), injection drug use (aOR: 0.75, 95% CI: 0.61–0.94) and past-year incarceration (aOR: 0.19, 95% CI: 0.10–0.33). Conclusions: The use of LDI has increased in BC in recent years. Markers of treatment experience were positively associated with receipt of LDI. A ssessment of outcomes associated with LDI is needed.

  • Open Access

    Facilitators of and barriers to buprenorphine initiation in the emergency department: a scoping review

    by Nikki Bozinoff, Erin Grennell, Charlene Soobiah, Zahraa Farhan, Terri Rodak, Christine Bucago, Katie Kingston, Michelle Klaiman, Brittany Poynter, Dominick Shelton, et al.


  • Open Access

    Examining inequities in access to opioid agonist treatment (OAT) take-home doses (THD): A Canadian OAT guideline synthesis and systematic review

    by Cayley Russell, Jenna Ashley, Farihah Ali, Nikki Bozinoff, Kim Corace, David C. Marsh, Christopher Mushquash, Jennifer Wyman, Maria Zhang, Shannon Lange